AstraZeneca plc (LON:AZN) has announced that positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in..

AstraZeneca plc (LON:AZN) Imfinzi has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III..

AstraZeneca plc (LON:AZN) Brilinta has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and..

AstraZeneca plc (LON:AZN) has announced that with effect from 1 November 2020, Diana Layfield is appointed as a Non-Executive Director. Diana Layfield is President, EMEA Partnerships at Google, driving technology..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo Company Limited’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application and has also been granted Priority Review in the US..

AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review in the US for the adjuvant treatment of patients with..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with..

AstraZeneca plc (LON:AZN) long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are..

AstraZeneca’s Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type-2 diabetes (T2D). CKD is a serious, progressive condition..

AstraZeneca PLC (LON:AZN) has announced that with effect from 1 October 2020, Dr Euan Ashley is appointed as a Non-Executive Director and a member of the Science Committee. Euan Ashley..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient..

High-level results from the OSTRO Phase III trial showed AstraZeneca plc (LON:AZN) Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in..

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal..

AstraZeneca plc (LON:AZN) has confirmed that the first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose..

AstraZeneca plc (LON:AZN) Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common..

AstraZeneca plc (LON:AZN) Breztri Aerosphere has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and..

AstraZeneca plc (LON:AZN) has announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Brilinta for the reduction of subsequent stroke..